Optimizing Injection Routes for Mouse In Vivo Transfection

The route of administration plays a pivotal role in the success of in vivo transfection experiments in mice. It determines not only where and how efficiently the genetic material is delivered, but also influences biodistribution, pharmacokinetics, immune activation, and transgene expression levels. Selecting the most appropriate injection route requires a detailed understanding of anatomical barriers, circulatory dynamics, and the biological behavior of the transfection reagent.

Intravenous (IV) injection via the tail vein is one of the most common methods for systemic delivery. This route enables broad distribution of transfection complexes throughout the circulation, allowing access to highly perfused organs like the liver, lungs, spleen, and kidneys. Lipid nanoparticle-based reagents typically accumulate in the liver due to fenestrated endothelium and apolipoprotein-mediated uptake by hepatocytes. While effective for hepatic delivery, IV injections may require higher doses to achieve meaningful transfection in less perfused tissues and are more likely to elicit systemic immune responses.

Intraperitoneal (IP) injection offers a simpler alternative with less technical demand. Upon administration, transfection complexes are absorbed through the peritoneal lining and enter systemic circulation via the portal vein, making this route suitable for liver and peritoneal tissue targeting. However, uptake kinetics are slower, and the degree of control over dosage reaching distal organs is reduced compared to IV.

For localized delivery, intratumoral (IT) injection ensures a high concentration of transfection complexes within the tumor microenvironment. This approach is ideal for xenograft studies aiming to silence or overexpress genes within tumor cells. IT injection bypasses systemic clearance, reduces off-target exposure, and minimizes immune activation. However, it does not model natural pharmacokinetics and may not reflect behavior in metastatic settings.

Intra-organ injections, such as intranasal, intracerebroventricular (ICV), or intrasplenic administration, are used to target specific tissues. Intranasal instillation is useful for pulmonary delivery, allowing direct access to lung epithelial cells with minimal systemic involvement. ICV injection delivers nucleic acids directly to the brain, bypassing the blood-brain barrier, while intrasplenic or intrahepatic injections localize gene delivery to immune or metabolic tissues, respectively. These methods provide high spatial specificity but require precision and expertise to avoid tissue damage or variability.

Subcutaneous (SC) injection is occasionally employed in dermal or muscular gene expression studies, or for slow-release depot formation. This route favors localized transfection and is often paired with polymer-based carriers that remain at the injection site for prolonged expression. However, it offers limited systemic distribution and is not suitable for targeting internal organs.

Oral and intragastric routes are rarely used in gene transfection due to enzymatic degradation in the gastrointestinal tract, unless specially formulated delivery systems such as enteric-coated nanoparticles are employed. Rectal and transdermal routes are similarly limited by permeability barriers.

Beyond choosing the route, key procedural variables must be optimized, including injection volume, rate of administration, nucleic acid concentration, and reagent-to-payload ratio. The mouse’s hydration status, anesthesia, and post-injection care also influence transfection outcomes and animal welfare.

Proper selection and optimization of injection routes are essential for reproducible and efficient in vivo gene delivery. They influence how the transfection agent reaches its target, how long it persists, and how strongly the host immune system reacts. By aligning the route of administration with organ-specific goals and reagent characteristics, researchers can significantly enhance the precision and translational relevance of their in vivo transfection models.